Symbols / DRMA
DRMA Chart
About
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.29M |
| Enterprise Value | -3.30M | Income | -8.85M | Sales | — |
| Book/sh | 4.69 | Cash/sh | 4.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | 0.09 | Forward P/E | -0.35 | PEG | — |
| P/S | — | P/B | 0.29 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 4.20 |
| Current Ratio | 4.56 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 15.24 | EPS next Y | -3.87 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -96.45% |
| ROE | -203.36% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.84M |
| Shs Float | 494.30K | Short Float | 1.26% | Short Ratio | 0.02 |
| Short Interest | — | 52W High | 23.70 | 52W Low | 1.11 |
| Beta | 0.60 | Avg Volume | 2.18M | Volume | 54.43K |
| Target Price | $10.00 | Recom | None | Prev Close | $1.33 |
| Price | $1.34 | Change | 0.76% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.34
Latest analyst target
3. DCF / Fair value
$-39.52
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.34
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-21 | main | Maxim Group | Buy → Buy | $10 |
| 2025-05-21 | main | Maxim Group | Buy → Buy | $3 |
| 2024-08-21 | main | Maxim Group | Buy → Buy | $6 |
| 2023-03-23 | main | Maxim Group | — → Buy | $4 |
- New Dermata marketing chief to launch Tome skincare line in 2026 - Stock Titan ue, 10 Mar 2026 12
- Will DRMA stock continue dividend increases - Inflation Watch & Proven Capital Preservation Tips - Naître et grandir Sat, 07 Mar 2026 18
- Once‑weekly acne treatment at home: Dermata’s new Tome skincare line - Stock Titan hu, 05 Mar 2026 14
- Dermata Therapeutics names Kyra Peckaitis VP of marketing - Investing.com India ue, 10 Mar 2026 13
- How (DRMA) Movements Inform Risk Allocation Models - Stock Traders Daily ue, 03 Mar 2026 22
- Market Movers | Winners: ADVB, KNRX, DRMA | Losers: MBRX, ALIT, DBGI - Trefis hu, 19 Feb 2026 08
- DRMA Stocks Thrive: Time for Action? - timothysykes.com Wed, 24 Dec 2025 08
- Guidance Update: Why is DRMA stock going down - Weekly Trade Recap & Community Driven Trade Alerts - baoquankhu1.vn Fri, 06 Mar 2026 16
- Dermata Therapeutics Announces Board Resignation and Size Reduction - TipRanks Wed, 25 Feb 2026 22
- Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today? - Stocktwits Wed, 24 Dec 2025 08
- Dermata lines up as much as $12.4M to help launch OTC acne kit - Stock Titan Wed, 24 Dec 2025 08
- Dermata Therapeutics to implement 1-for-10 reverse stock split on August 1 - Investing.com Wed, 30 Jul 2025 07
- 3.3M Australians with acne: Dermata's new treatment patent - Stock Titan ue, 20 Jan 2026 08
- Dermata Therapeutics stock soars after securing $4.1 million private placement - Investing.com Wed, 24 Dec 2025 08
- Dermata Therapeutics (NASDAQ: DRMA) teases OTC brand, plans 2026 acne kit launch - Stock Titan hu, 04 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 612745 | — | — | Stock Award(Grant) at price 0.00 per share. | PROEHL GERALD T | Chief Executive Officer | — | 2025-12-23 00:00:00 | I |
| 1 | 122549 | — | — | Stock Award(Grant) at price 0.00 per share. | VAN HOOSE KYRI K | Chief Financial Officer | — | 2025-12-23 00:00:00 | D |
| 2 | 78741 | — | — | Stock Award(Grant) at price 0.00 per share. | HALE DAVID F | Director | — | 2025-01-23 00:00:00 | I |
| 3 | 196851 | — | — | Stock Award(Grant) at price 0.00 per share. | FISHER MARY | Director | — | 2025-01-21 00:00:00 | D |
| 4 | 78741 | — | — | Stock Award(Grant) at price 0.00 per share. | VAN HOOSE KYRI K | Chief Financial Officer | — | 2025-01-21 00:00:00 | D |
| 5 | 787402 | — | — | Stock Award(Grant) at price 0.00 per share. | PROEHL GERALD T | Chief Executive Officer | — | 2025-01-21 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -12.51M | -8.04M | -9.67M | -7.86M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.29M | -7.79M | -9.61M | -7.90M |
| ReconciledDepreciation | 0.00 | |||
| EBITDA | -12.51M | -8.04M | -9.67M | -7.86M |
| EBIT | -12.51M | -8.04M | -9.67M | -7.86M |
| NetInterestIncome | 225.78K | 247.22K | 63.57K | -45.61K |
| InterestExpense | -63.57K | 45.61K | ||
| InterestIncome | 225.78K | 247.22K | 63.57K | |
| NormalizedIncome | -12.29M | -7.79M | -9.61M | -7.90M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.29M | -7.79M | -9.61M | -7.90M |
| TotalExpenses | 12.51M | 8.04M | 9.67M | 7.86M |
| TotalOperatingIncomeAsReported | -12.51M | -8.04M | -9.67M | -7.86M |
| DilutedAverageShares | 152.98K | 19.49K | 4.60K | 1.79K |
| BasicAverageShares | 152.98K | 19.49K | 4.60K | 1.79K |
| DilutedEPS | -80.30 | -399.90 | -2.09K | -5.83K |
| BasicEPS | -80.30 | -399.90 | -2.09K | -5.83K |
| DilutedNIAvailtoComStockholders | -12.29M | -7.79M | -9.61M | -10.46M |
| NetIncomeCommonStockholders | -12.29M | -7.79M | -9.61M | -10.46M |
| PreferredStockDividends | 2.56M | |||
| NetIncome | -12.29M | -7.79M | -9.61M | -7.90M |
| NetIncomeIncludingNoncontrollingInterests | -12.29M | -7.79M | -9.61M | -7.90M |
| NetIncomeContinuousOperations | -12.29M | -7.79M | -9.61M | -7.90M |
| PretaxIncome | -12.29M | -7.79M | -9.61M | -7.90M |
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 225.78K | 247.22K | 63.57K | -45.61K |
| TotalOtherFinanceCost | -63.57K | 45.61K | ||
| InterestExpenseNonOperating | -63.57K | 45.61K | ||
| InterestIncomeNonOperating | 225.78K | 247.22K | 63.57K | |
| OperatingIncome | -12.51M | -8.04M | -9.67M | -7.86M |
| OperatingExpense | 12.51M | 8.04M | 9.67M | 7.86M |
| ResearchAndDevelopment | 8.20M | 4.07M | 5.65M | 3.46M |
| SellingGeneralAndAdministration | 4.31M | 3.97M | 4.02M | 4.40M |
| GeneralAndAdministrativeExpense | 4.31M | 3.97M | 4.02M | 4.40M |
| OtherGandA | 4.31M | 3.97M | 4.02M | 4.40M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 251.78K | 26.20K | 5.13K | 3.47K |
| ShareIssued | 251.78K | 26.20K | 5.13K | 3.47K |
| TangibleBookValue | 1.56M | 6.36M | 6.02M | 10.11M |
| InvestedCapital | 1.56M | 6.36M | 6.02M | 10.11M |
| WorkingCapital | 1.56M | 6.36M | 6.02M | 10.11M |
| NetTangibleAssets | 1.56M | 6.36M | 6.02M | 10.11M |
| CommonStockEquity | 1.56M | 6.36M | 6.02M | 10.11M |
| TotalCapitalization | 1.56M | 6.36M | 6.02M | 10.11M |
| TotalEquityGrossMinorityInterest | 1.56M | 6.36M | 6.02M | 10.11M |
| StockholdersEquity | 1.56M | 6.36M | 6.02M | 10.11M |
| RetainedEarnings | -65.68M | -53.39M | -45.59M | -35.98M |
| AdditionalPaidInCapital | 67.24M | 59.74M | 51.61M | 46.09M |
| CapitalStock | 252.00 | 26.00 | 77.00 | 833.00 |
| CommonStock | 252.00 | 26.00 | 77.00 | 833.00 |
| TotalLiabilitiesNetMinorityInterest | 1.97M | 1.62M | 922.63K | 1.52M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 1.97M | 1.62M | 922.63K | 1.52M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 731.63K | 716.49K | 170.39K | 766.21K |
| PayablesAndAccruedExpenses | 1.24M | 907.13K | 752.25K | 750.63K |
| CurrentAccruedExpenses | 433.15K | 41.10K | 255.54K | 235.38K |
| InterestPayable | 0.00 | |||
| Payables | 808.01K | 866.03K | 496.70K | 515.25K |
| AccountsPayable | 808.01K | 866.03K | 496.70K | 515.25K |
| TotalAssets | 3.53M | 7.98M | 6.94M | 11.62M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.53M | 7.98M | 6.94M | 11.62M |
| OtherCurrentAssets | 14.50K | 11.60K | ||
| CurrentDeferredAssets | 0.00 | 55.72K | ||
| PrepaidAssets | 372.32K | 540.50K | 690.59K | 769.42K |
| Receivables | 8.36K | 12.60K | ||
| OtherReceivables | 12.60K | |||
| AccruedInterestReceivable | 8.36K | 12.60K | ||
| CashCashEquivalentsAndShortTermInvestments | 3.16M | 7.44M | 6.24M | 10.80M |
| CashAndCashEquivalents | 3.16M | 7.44M | 6.24M | 10.80M |
| CashFinancial | 10.80M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -11.16M | -6.41M | -8.83M | -5.69M |
| RepurchaseOfCapitalStock | -828.00 | -40.00 | 0.00 | -1.00M |
| RepaymentOfDebt | 0.00 | -556.48K | ||
| IssuanceOfDebt | 0.00 | 1.56M | ||
| IssuanceOfCapitalStock | 6.89M | 7.61M | 4.28M | 15.96M |
| InterestPaidSupplementalData | 0.00 | 1.42K | ||
| IncomeTaxPaidSupplementalData | 950.00 | 950.00 | 950.00 | 1.40K |
| EndCashPosition | 3.16M | 7.44M | 6.24M | 10.80M |
| BeginningCashPosition | 7.44M | 6.24M | 10.80M | 530.40K |
| ChangesInCash | -4.28M | 1.20M | -4.56M | 10.27M |
| FinancingCashFlow | 6.89M | 7.61M | 4.28M | 15.96M |
| CashFlowFromContinuingFinancingActivities | 6.89M | 7.61M | 4.28M | 15.96M |
| ProceedsFromStockOptionExercised | 1.11K | 187.00 | 287.00 | 0.00 |
| NetPreferredStockIssuance | 0.00 | -430.00K | ||
| PreferredStockPayments | 0.00 | -1.00M | ||
| PreferredStockIssuance | 0.00 | 570.00K | ||
| NetCommonStockIssuance | 6.89M | 7.61M | 4.28M | 15.39M |
| CommonStockPayments | -828.00 | -40.00 | 0.00 | |
| CommonStockIssuance | 6.89M | 7.61M | 4.28M | 15.39M |
| NetIssuancePaymentsOfDebt | 0.00 | 1.01M | ||
| NetShortTermDebtIssuance | 1.01M | |||
| ShortTermDebtPayments | -556.48K | |||
| ShortTermDebtIssuance | 1.56M | |||
| NetLongTermDebtIssuance | 0.00 | 1.01M | ||
| LongTermDebtPayments | 0.00 | -556.48K | ||
| LongTermDebtIssuance | 0.00 | 1.56M | ||
| OperatingCashFlow | -11.16M | -6.41M | -8.83M | -5.69M |
| CashFlowFromContinuingOperatingActivities | -11.16M | -6.41M | -8.83M | -5.69M |
| ChangeInWorkingCapital | 466.86K | 863.68K | -153.58K | 289.55K |
| ChangeInOtherCurrentLiabilities | 0.00 | |||
| ChangeInPayablesAndAccruedExpense | 298.68K | 700.98K | -275.52K | 1.04M |
| ChangeInAccruedExpense | 407.19K | 331.66K | -256.97K | 628.66K |
| ChangeInPayable | -108.51K | 369.33K | -18.54K | 410.97K |
| ChangeInAccountPayable | -108.51K | 369.33K | -18.54K | 410.97K |
| ChangeInPrepaidAssets | 168.18K | 162.69K | 121.94K | -750.08K |
| OtherNonCashItems | 14.13K | |||
| StockBasedCompensation | 657.65K | 522.08K | 930.33K | 1.91M |
| DepreciationAmortizationDepletion | 0.00 | |||
| DepreciationAndAmortization | 0.00 | |||
| Depreciation | 0.00 | |||
| NetIncomeFromContinuingOperations | -12.29M | -7.79M | -9.61M | -7.90M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DRMA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|